drugset
Drugs / n-3PUFA
last change Dec 2021 re-read 3 minutes ago

n-3PUFA

also known as n-3 polyunsaturated fatty acids · omega-3 fatty acids
Developed for
heart failure
Investigated by
Gruppo di Ricerca GISSI · Mayo Clinic · National Center for Research Resources (NCRR) · National Institute on Aging (NIA)

Trials 2

today NCT03350906 · Ph 3 NCT00336336 · Ph 3
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT03350906 Jan 2018 → Dec 2021 — Mayo Clinic Completed No outcome recorded
Phase 3 NCT00336336 Aug 2002 → Apr 2008 heart failure Gruppo di Ricerca GISSI Completed Mixed

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as n-3PUFA “The antiarrhythmic effects of n-3 polyunsaturated fatty acids (n-3PUFA) in ischemic heart disease have been demonstrated” PMID 21315217 ↗ Feb 2011
2

NCT03350906 ↗

NCT00336336 ↗
Known as n-3 polyunsaturated fatty acids “Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure” PMID 18757090 ↗ Aug 2008
Known as omega-3 fatty acids “suppressing chronic inflammation using omega-3 fatty acids (n3-PUFA) restores skeletal muscle function and exercise responsiveness in older adults.” NCT03350906 ↗
Route Oral “1 g die per os” NCT00336336 ↗